Literature DB >> 10890195

A boy with normal growth in spite of growth hormone deficiency after resection of a suprasellar teratoma.

K Araki1, M Koga, T Okada, T Kurashige, K Naruse, M Hiroi.   

Abstract

We reported a boy with panhypopituitarism after removal of a suprasellar teratoma and pituitary stalk transection at the age of 3 months. His growth was accelerated after 5 years of age without growth hormone (GH) therapy, although he had poor height growth until age 4 under treatment with hydrocortisone, levothyroxine sodium, and desamino-D-arginine vasopressin (DDAVP). Hyperphagia and obesity developed after surgery. Endocrinological examination revealed no GH response to glucagon, low serum levels of insulin-like growth factor (IGF)-1 and IGF binding protein-3 (IGFBP-3). Serum prolactin was normal, but serum insulin was high. Some patients who received an operation for craniopharyngioma were reported to achieve normal growth without GH secretion, but the mechanism is still unknown. High serum levels of prolactin or insulin can be associated with normal IGF in GH deficient patients. This patient had obesity and high serum insulin, which may be related to growth without GH secretion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10890195     DOI: 10.1507/endocrj.47.supplmarch_s101

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  3 in total

1.  Hyperinsulinemia may promote growth without GH in children after resection of suprasellar brain tumors.

Authors:  Hideyuki Iwayama; Takashi Kamijo; Norishi Ueda
Journal:  Endocrine       Date:  2011-06-03       Impact factor: 3.633

Review 2.  Clinical management of teratoma, a rare hypothalamic-pituitary neoplasia.

Authors:  S Chiloiro; A Giampietro; A Bianchi; L De Marinis
Journal:  Endocrine       Date:  2015-12-23       Impact factor: 3.633

Review 3.  Suprasellar Mature Cystic Teratoma Mimicking Rathke's Cleft Cyst: A Case Report and Systematic Review of the Literature.

Authors:  Shenzhong Jiang; Zhaojian Wang; Yan You; Renzhi Wang; Xinjie Bao
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-30       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.